SageView Advisory Group LLC Makes New Investment in Sanofi $SNY

Key Points

• SageView Advisory Group bought a new stake of 30,550 Sanofi shares in Q3, valued at approximately $1.44 million, per its most recent 13F filing.
• Hedge funds and other institutional investors own about 14.03% of Sanofi, with several managers (notably AQR Capital, which more than doubled its stake) adding to positions in recent quarters.
• Analysts have a consensus rating of Hold on Sanofi with an average price target of $62.67, though research notes are mixed—some firms reaffirmed buys while others trimmed ratings to neutral.

SageView Advisory Group LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,550 shares of the company's stock, valued at approximately $1,442,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC increased its stake in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock valued at $1,693,000 after buying an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock valued at $2,732,000 after acquiring an additional 752 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company's stock valued at $326,000 after acquiring an additional 347 shares during the last quarter. Finally, Savant Capital LLC increased its position in Sanofi by 17.1% during the 2nd quarter. Savant Capital LLC now owns 8,423 shares of the company's stock valued at $407,000 after buying an additional 1,227 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company's stock.

Sanofi Stock Performance

Shares of SNY stock opened at $43.94 on Thursday. Sanofi has a one year low of $43.34 and a one year high of $59.17. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The firm's 50 day moving average price is $47.04 and its 200-day moving average price is $48.32. The firm has a market cap of $107.17 billion, a P/E ratio of 12.21, a P/E/G ratio of 1.14 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Sanofi in a research note on Friday, January 16th. Guggenheim lowered Sanofi from a "buy" rating to a "neutral" rating in a research report on Tuesday, December 9th. Bank of America lowered shares of Sanofi from a "buy" rating to a "neutral" rating in a research report on Thursday, February 12th. Wall Street Zen cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Finally, UBS Group reiterated a "neutral" rating on shares of Sanofi in a research note on Friday, January 16th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $62.67.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.